LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
3.03 USD
-2.26%
Market Closed
Updated:
May 4, 2024
LAVA Therapeutics NV
Cash from Operating Activities
|
LAVA Therapeutics NV
Cash from Operating Activities Peer Comparison
Comparables:
PHARM
QURE
ARGX
MRUS
N
NAMS
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cash from Operating Activities
-$39m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Cash from Operating Activities
-$17.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Cash from Operating Activities
-$145.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-39%
|
|
|
argenx SE
XBRU:ARGX
|
Cash from Operating Activities
-$420.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Cash from Operating Activities
-$142.2m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Cash from Operating Activities
€8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LAVA Therapeutics NV's Cash from Operating Activities?
Cash from Operating Activities
-39m
USD
-39m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Cash from Operating Activities amounts to -39m USD.
What is LAVA Therapeutics NV's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-61%
-61%
The average annual Cash from Operating Activities growth rates for LAVA Therapeutics NV have been -61% over the past three years .
You don't have any saved screeners yet
